Hyman, Phelps & McNamara, P.C.
Washington, District of Columbia OfficeView all offices
700 Thirteenth Street, N.W., Suite 1200
Washington, District of Columbia
|Profile Visibility |
|#49 in weekly profile views out of 2,781 law firms in Washington, District of Columbia|
|#2,629 in weekly profile views out of 271,019 total law firms Overall|
Office Hours:Monday: 08:30 AM-06:30 PM
Tuesday: 08:30 AM-06:30 PM
Wednesday: 08:30 AM-06:30 PM
Thursday: 08:30 AM-06:30 PM
Friday: 08:30 AM-06:30 PM
About this office:
Hyman, Phelps & McNamara, P.C. is a law firm that advises and represents a broad range of clients on legal issues concerning food, drug, medical device and cosmetic law and regulation. To complement its core expertise in FDA matters, the firm also serves its clients in related areas, such as advertising, controlled substance regulation, health care fraud and abuse, reimbursement, pricing laws and government contracts. In 1980, three former U.S. Food and Drug Administration (FDA) lawyers opened the firm in Washington, D.C. to concentrate in this area of the law. Hyman, Phelps & McNamara, P.C. now has one of the most extensive food and drug practices in the United States.
Statement of Practice Summary:
Practice before all Courts, Government Agencies, International Regulatory Authorities involving Foods, Drugs, Cosmetics, Medical Devices, Biologics, Pesticides, Health Care, Controlled Substances and Consumer Products.
Documents by Lawyers at this office
AMA Tells Pharmacists: “Don’t Call Us We’ll Call You”
Larry K. Houck, June 14, 2013
Pharmacists are under increasing pressure to take extraordinary steps to verify prescriptions for controlled substances, especially in light of the fact that the Drug Enforcement Administration (“DEA”) has asserted that pharmacists are the gatekeepers or the “last line of...
Striding Towards Greater Access of Clinical Trials Data and Results
David B. Clissold,James E. Valentine, June 14, 2013
The pendulum has been swinging: the medical research community and public health advocates want access to clinical trials data used to support marketing applications of FDA-regulated medical products. In 2007 that pendulum picked up momentum, with the enactment of Section 801 of the FDA Amendments...
Year Established: 1980